Aerska Secures $39M Funding In Series A Round

The funding will accelerate development of its brain shuttle platform to enhance delivery of RNAi therapeutics across the blood-brain barrier for neurological disorders.

This round brings Aerska’s total funding to $60 million, following its seed round in October 2025. The proceeds will support continued advancement of the company’s antibody-oligo conjugate (AOC) platform as it moves toward clinical development for systemically delivered RNAi therapeutics targeting neurological diseases.

Aerska’s AOC platform aims to pioneer systemically delivered RNA medicines capable of reaching the brain to address CNS diseases at their source. Its proprietary brain shuttle technology overcomes the blood-brain barrier a key obstacle that has limited RNA therapeutics in the CNS.

Read Also - UK Fintech Sidekick Raises £7.8M Funding In Series A Round

The approach is designed for intravenous or subcutaneous administration, enabling uniform, deep brain distribution and durable gene knockdown unlocking new therapeutic opportunities for neurological disorders.

“The ability to systemically administer RNAi therapies to the brain unlocks a powerful new approach to treating neurodegeneration,” said Jack O’Meara, CEO & Co-Founder, Aerska. “Partnering with EQT Dementia Fund further strengthens our path to the clinic as we work to translate this capability into meaningful therapies for the treatment of genetically-driven forms of Alzheimer’s disease and other devastating brain disorders.”

“For families facing diseases like Alzheimer’s, Aerska’s approach offers hope for preserving cognitive function and quality of life” said Philip Scheltens, Partner and Head of the Dementia Fund EQT Life Sciences. “The team’s strategy of upstream intervention, combined with a focus on the genetic forms of neurological disease, positions them to transform outcomes for populations who have been underserved by current therapeutic approaches. We really look forward to working with this talented team to advance this groundbreaking platform.”

As part of the financing, Arno de Wilde, Managing Director at EQT; Philip Scheltens, Partner and Head of the Dementia Fund at EQT; and Alex Colville, General Partner at age1, will join Aerska’s Board of Directors.

About Aerska

Aerska is a biotechnology company pioneering RNA medicines to treat, delay and prevent diseases of the brain. The company is leveraging advances in ‘brain shuttles’ to enable targeted delivery of next-generation RNAi therapeutics to the CNS. By silencing the genes that cause harm, Aerska aims to preserve the minds, protect the memories, and enable our loved ones to live longer, healthier lives.